Praxis Precision Medicines (PRAX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PRAX Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Praxis Precision Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$258.13 |
| 52 Week High | US$278.44 |
| 52 Week Low | US$26.70 |
| Beta | 2.98 |
| 1 Month Change | 53.75% |
| 3 Month Change | 554.82% |
| 1 Year Change | 243.58% |
| 3 Year Change | 591.11% |
| 5 Year Change | -60.75% |
| Change since IPO | -38.10% |
Recent News & Updates
Recent updates
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026
Dec 05We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Jul 18
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Apr 04Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Mar 04Praxis Precision Medicines: Multiple Potential Drivers
Dec 26Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation
Dec 13Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10Shareholder Returns
| PRAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 38.7% | -3.1% | 0.07% |
| 1Y | 243.6% | 14.8% | 11.9% |
Return vs Industry: PRAX exceeded the US Biotechs industry which returned 16.6% over the past year.
Return vs Market: PRAX exceeded the US Market which returned 12.6% over the past year.
Price Volatility
| PRAX volatility | |
|---|---|
| PRAX Average Weekly Movement | 53.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRAX's weekly volatility has increased from 29% to 54% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 116 | Marcio De'Souza | praxismedicines.com |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050.
Praxis Precision Medicines, Inc. Fundamentals Summary
| PRAX fundamental statistics | |
|---|---|
| Market cap | US$6.46b |
| Earnings (TTM) | -US$273.04m |
| Revenue (TTM) | US$7.46m |
Is PRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRAX income statement (TTM) | |
|---|---|
| Revenue | US$7.46m |
| Cost of Revenue | US$245.90m |
| Gross Profit | -US$238.43m |
| Other Expenses | US$34.60m |
| Earnings | -US$273.04m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.92 |
| Gross Margin | -3,194.88% |
| Net Profit Margin | -3,658.53% |
| Debt/Equity Ratio | 0% |
How did PRAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 10:01 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |